Replies to post #83524 on Bioelectronics Corp (BIEL)

[NoPinkScams]

Vague? I think I've been pretty specific. My accusations mirror those of the SEC, namely:

1) Andy and Kelly have stolen millions of dollars from common shareholders via an illegal share dilution scam.

2) Andy intentionally overstated revenue from fake bill and hold transactions for the sole purpose of pumping up the share price

Additionally,

3) BIEL is misleading shareholders as to the current FDA status regarding OTC approval. They already know that OTC via 510 k is not a viable path.

4) The currently available clinical trial data for Actipatch is insufficient to prove efficacy of the product.


This is what I believe and will continue to believe until proven wrong.

[Det_Robert_Thorne]

Companies rarely tell more than what's publicly disclosed

IMO, because of selective disclosure laws, calling a company is a pointless excercise. They'll only tell the caller what they've previously disclosed, though they might expand on things a bit, and they'll only spin the story in an absolutely positive manner.

In addition, once you develop a personal relationship with principles at a company (since sometimes pink sheet CEOs or high level execs will talk to shareholders,) some objectivity will be lost.

All of the info one needs to know is in the public information in press releases or filed with OTCMarkets and the SEC. In BIEL's case, you can also add any public info from the FDA.

Once you're looked into a few of these companies, it's pretty easy to extrapolate pretty solid forecasts from the public data, and one has to be able to read between the lines.